中国浙江2009-2013年耐多药结核患者治疗转归
该前瞻性观察队列纳入浙江六地区2009-2013年连续耐多药结核患者,由感染病专家制定方案并记录24个月转归。537例已知转归者中治疗成功374例(69.6%),失败101例(18.8%)、死亡36例(6.7%)、失访26例(4.8%)。年龄>60岁、复治、既往治疗失败、空洞病变及不良事件为不良转归独立预测因素,标准化方案与较低风险相关。
要点
- 537例耐多药结核患者治疗成功率为69.6%(374/537)。
- 空洞病变(HR 4.9)、年龄>60岁(HR 2.3)与不良转归独立相关。
- 建议对所有二线抗结核药物开展药敏试验以辅助治疗。
核心结论
- 在良好设计的治疗与管理方案下,高耐多药结核负担国家也可获得较高的治疗成功率。
- 建议对所有二线抗结核药物开展药敏试验,以进一步辅助耐多药结核治疗。
研究设计与样本
- 前瞻性观察性队列研究,纳入2009至2013年中国浙江省六个地区的连续耐多药结核患者。
- 共观察820例耐多药结核患者,其中537例已知治疗转归者纳入分析。
- 由感染病专科医生制定治疗方案,通过结构化问卷收集社会人口学特征。
- 主要终点为24个月时的不良治疗转归,包括微生物学持续阳性的治疗失败、失访或死亡。
- 采用Cox比例风险模型评估不良治疗转归的危险因素。
主要发现
- 537例已知转归患者中,治疗成功374例(69.6%),按100人年计为40.2。
- 治疗失败101例(18.8%,10.0/100人年),死亡36例(6.7%,3.4/100人年),失访26例(4.8%,2.7/100人年)。
- 年龄>60岁(HR 2.3,95%CI 1.2-4.2)与不良转归独立相关。
- 登记为复发(HR 2.2,95%CI 1.1-4.4)及登记为治疗失败后治疗(HR 2.4,95%CI 1.2-4.9)与不良转归独立相关。
- 使用标准化耐多药结核方案(HR 0.6,95%CI 0.4-1.0)、空洞病变(HR 4.9,95%CI 2.8-8.6)及不良事件(HR 2.5,95%CI 1.2-5.5)与不良转归相关。
临床怎么用
- 对耐多药结核患者应评估年龄、既往治疗史、空洞病变及不良事件等不良转归风险因素。
- 治疗中需关注不良事件,其与不良治疗转归独立相关。
- 应尽量对所有二线抗结核药物开展药敏试验以指导方案制定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To examine treatment outcomes and factors associated with poor outcome of multidrug-resistant (MDR) tuberculosis (TB) in China. METHODS: We conducted a prospective observational cohort study including consecutive patients with MDR-TB between 2009 and 2013 in six regions of Zhejiang province. Patients were prescribed treatments by infectious disease specialists, and treatment outcomes were recorded. Sociodemographic characteristics were obtained through a structured questionnaire. The primary endpoint was poor treatment outcomes, defined as treatment failure based on microbiologic persistence, default (lost to follow-up) or death at 24 months. We assessed risk factors for poor treatment outcomes using a Cox proportional hazards model. RESULTS: A total of 820 MDR-TB patients were observed, and 537 with known treatment outcomes were included in our study. Overall, the treatment success rate was 40.2 per 100 years (374/537 participants, 69.6%), while treatment failure, death and default rates were 10.0 per 100 years (101 participants, 18.8%), 3.4 per 100 years (36 participants, 6.7%) and 2.7 per 100 years (26 participants, 4.8%) respectively. Independent predictors of poor treatment outcomes included age >60 years (hazard ratio (HR) 2.3, 95% confidence interval (CI) 1.2-4.2), patients registered as experiencing relapse (HR 2.2, 95% CI 1.1-4.4), patients registered as receiving treatment after failure (HR 2.4, 95% CI 1.2-4.9), use of standardized MDR-TB regimens (HR 0.6, 95% CI 0.4-1.0), cavitary disease (HR 4.9, 95% CI 2.8-8.6) and adverse events (HR 2.5, 95% CI 1.2-5.5). CONCLUSIONS: Under well-designed treatment and management scheme, high treatment success rates were achieved in a high-MDR-TB-burden country. Antimicrobial susceptibility testing for all second-line drugs should be conducted to further assist in the treatment of MDR-TB.
引用
- Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013. Clin Microbiol Infect. 2017. PMID: 28712668. doi:10.1016/j.cmi.2017.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。